Supervisor Database Search
Guidance for ICAT Supervisors
The ICAT Supervisor list is reviewed annually by the partner universities and updated online in March/April each year.
You can read about the ICAT supervisor selection process and eligibility criteria below:
Terms of reference/guide to supervising ICAT Fellows.
You can read the terms of reference for supervisors actively supervising ICAT Fellows below:
Supervisor Database
Search for supervisors below. You can filter your search using the options and select multiple fields by holding CTRL (Cmd on Mac) + clicking multiple options in a list.
Full NameProfessor Osama Soliman
- genetics, genomics and molecular biology
- bioengineering/medical devices
- artificial intelligence/machine learning/data analytics
- preventive medicine/behavioural change interventions
- clinical trials
- Medicine
- Cardiology
- Clinical Trials
- Vascular Medicine
Prof. Dr. Osama Soliman is an internationally recognized academic consultant cardiologist and a pioneer in Precision Cardiovascular Medicine. He has over 27 years of clinical and academic experience, with extensive expertise in advanced cardiovascular imaging, structural heart interventions, heart failure, and digital health innovation.
Professor Soliman currently serves as Professor of Precision Cardiovascular Medicine and Innovation at RCSI and Deputy Director of the Cardiovascular Research Institute Dublin (CVRI), where he leads the development of AI-powered imaging Core Labs and cardiovascular digital twin technologies. He is also a Consultant Cardiologist at the Mater Private Network, Dublin.
He has authored over 400 peer-reviewed publications, developed several international patient registries and clinical trials (including EuroEchoVAD, EuroLevoVAD, EEVAD, UCARE, I-CARE, AI-SHEILD, and INCEPTION), and leads multi-million euro research programs funded by Industry, the EU, HRB, and SFI. He is the recipient of the EIC Transition Grant (2025) and a co-Principal Investigator of the HeartWise RVAD development consortium.
Our group at the Cardiovascular Research Institute Dublin (CVRI) and the Royal College of Surgeons in Ireland (RCSI) offers an internationally leading environment for translational cardiovascular research, bridging advanced imaging, artificial intelligence, and precision medicine.
We welcome PhD candidates interested in impactful projects that address unmet clinical needs in cardiovascular disease using state-of-the-art technologies. Examples of potential projects include:
Advanced Multimodality Imaging in Heart Failure and Structural Heart Disease
Leveraging echocardiography, CT, and cardiac MRI datasets, this project will develop imaging-based biomarkers for diagnosis, prognosis, and therapy response in patients with heart failure or valvular heart disease. Integration of image-based metrics with clinical and laboratory data will enable phenotype stratification.
Artificial Intelligence and Risk Prediction Models in Cardio-Oncology
Using real-world data from breast cancer patients undergoing chemotherapy, this project will apply machine learning to develop and validate predictive models for cardiotoxicity. The aim is to personalize cardiovascular surveillance strategies in oncology settings.
Ethnic and Sex-Specific Determinants of Cardiometabolic Risk and Atherosclerosis
This project involves advanced data analysis from multinational cohorts to study disparities in cardiovascular risk and plaque characteristics across diverse populations, using imaging and clinical data.
All projects will benefit from access to well-characterized prospective registries, a dedicated cardiovascular imaging core lab, and mentorship from an interdisciplinary team. The PhD programme includes training in advanced imaging interpretation, machine learning, statistical modelling, and academic writing, with opportunities for collaboration with clinical, academic, and industry partners.
These projects are ideal for motivated candidates with a background in medicine, biomedical science, bioengineering, or data science, aiming to impact patient care through translational cardiovascular research.